Professor | Yichen Xu | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Yichen Xu
Contact Information	yichen_xu@zju.edu.cn
Language ability	English, Chinese
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Yichen Xu

Contact Information

yichen_xu@zju.edu.cn

Language ability

English, Chinese

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Pharmaceutical Sciences
Academic Background & Achievements	2020.12-Present: Hundred Talents Program Researcher, Zhejiang University 2016.1-2020.11: Postdoctoral Researcher, University of California, San Francisco 2011.9-2015.10: PhD in Medicine, Imperial College London 2007.9-2011.6: Bachelor of Science in Biochemistry, Nanjing University National-level Youth Talent Project Zhejiang Provincial Outstanding Youth Fund Recipient
Work Experience	2020.12-Present - Zhejiang University - Hundred Talents Program Researcher 2016.1-2020.11 - University of California, San Francisco - Postdoctoral Researcher 2011.9-2015.10 - Imperial College London - PhD Student 2007.9-2011.6 - Nanjing University - Bachelor Student
Awards	Damon Runyon Fellowship Award (Year not mentioned): One of 10-15 recipients annually in the USA Imperial College London Annual Master's Award (Year not mentioned)

University/Lab Affiliation and Title

Zhejiang University

Faculty

Pharmaceutical Sciences

Academic Background & Achievements

2020.12-Present: Hundred Talents Program Researcher, Zhejiang University
2016.1-2020.11: Postdoctoral Researcher, University of California, San Francisco
2011.9-2015.10: PhD in Medicine, Imperial College London
2007.9-2011.6: Bachelor of Science in Biochemistry, Nanjing University
National-level Youth Talent Project
Zhejiang Provincial Outstanding Youth Fund Recipient

Work Experience

2020.12-Present - Zhejiang University - Hundred Talents Program Researcher
2016.1-2020.11 - University of California, San Francisco - Postdoctoral Researcher
2011.9-2015.10 - Imperial College London - PhD Student
2007.9-2011.6 - Nanjing University - Bachelor Student

Awards

Damon Runyon Fellowship Award (Year not mentioned): One of 10-15 recipients annually in the USA
Imperial College London Annual Master's Award (Year not mentioned)

Areas of Focus	Tumor Pharmacology mRNA Translation Regulation Mechanisms and Drug Targeting
Publications	ERα is a non-canonical RNA binding protein sustaining tumor cell survival and drug resistance, Xu Y, Huang P, Wang Y, Xue L, Devericks E, Nguyen H, Yu X, Oses-Prieto J, Burlingame A, Miglani S, Goodarzi H, Ruggero D, 2021 The methyltransferase PRMT1 regulates γ-globin translation, Wang Y, Li X, Ge J, Liu M, Pang X, Liu J, Luo C, Xu Y, Zhao Q, 2021 Examining Myc-Dependent Translation Changes in Cellular Homeostasis and Cancer, Kovalski J, Xu Y, Ruggero D, 2021 The role of translation control in tumorigenesis and its therapeutic implications, Xu Y, Ruggero D, 2020 An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers, Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ, 2020 Translation control of the immune checkpoint in cancer and its therapeutic targeting, Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y, Stumpf CR, Ruggero D, 2019 Nuclear TARBP2 drives oncogenic dysregulation of RNA splicing and decay, Fish L, Navickas A, Culbertson B, Xu Y, Nguyen HCB, Zhang S, Hochman M, Okimoto R, Dill BD, Molina H, Najafabadi HS, Claudio Alarcón, Ruggero D, Goodarzi H, 2019 LMTK3 Represses Tumour Suppressor-Like Genes through Chromatin Remodeling in Breast Cancer, Xu Y, Zhang H, Nguyen V, Angelopoulos N, Nunes J, Reid A, Buluwela L, Magnani L, Stebbing J, Giamas G, 2015 The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin beta(1), Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, Lombardo Y, Frampton AE, Green AR, Ellis IO, Ali S, Lenz HJ, Thanou M, Stebbing J, Giamas G, 2014 Broader implications of SILAC-based proteomics for dissecting signaling dynamics in cancer, Zhang H, Xu Y, Papanastasopoulos P, Stebbing J, Giamas G, 2014 Targeting lemurs against cancer metastasis, Xu Y, Zhang H, Giamas G, 2014 Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics, Liu TY, Huang HH, Wheeler D, Xu Y, Wells JA, Song YS, Wiita AP, 2017 Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics, Stebbing J, Zhang H, Xu Y, Grothey A, Ajuh P, Angelopoulos N, Giamas G, 2015 KSR1 regulates BRCA1 degradation and inhibits breast cancer growth, Stebbing J, Zhang H, Xu Y, Lit LC, Green AR, Grothey A, Lombardo Y, Periyasamy M, Blighe K, Zhang W, Shaw JA, Ellis IO, Lenz HJ, Giamas G, 2015 Proteomic profile of KSR1-regulated signaling in response to genotoxic agents in breast cancer, Zhang H, Angelopoulos N, Xu Y, Grothey A, Nunes J, Stebbing J, Giamas G, 2015 LMTK3 is implicated in endocrine resistance via multiple signaling pathways, Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, Miki Y, Chow LW, Coombes RC, Sasano H, Shaw JA, Giamas G, 2013 SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1, Zhang H, Xu Y, Filipovic A, Lit LC, Koo CY, Stebbing J, Giamas G, 2013 Oestrogen attenuates tumour progression in hepatocellular carcinoma, Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J, Zhang W, Han X, Tan R, Shen P, 2012 Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs), Yang W, Lu Y, Xu Y, Xu L, Zheng W, Wu Y, Li L, Shen P, 2012 Proteomic profile of KSR1-regulated signaling in response to genotoxic agents in breast cancer, Angelopoulos N, Stebbing J, Xu Y, Giamas G, Zhang H, 2016

Areas of Focus

Tumor Pharmacology
mRNA Translation Regulation Mechanisms and Drug Targeting

Publications

ERα is a non-canonical RNA binding protein sustaining tumor cell survival and drug resistance, Xu Y, Huang P, Wang Y, Xue L, Devericks E, Nguyen H, Yu X, Oses-Prieto J, Burlingame A, Miglani S, Goodarzi H, Ruggero D, 2021
The methyltransferase PRMT1 regulates γ-globin translation, Wang Y, Li X, Ge J, Liu M, Pang X, Liu J, Luo C, Xu Y, Zhao Q, 2021
Examining Myc-Dependent Translation Changes in Cellular Homeostasis and Cancer, Kovalski J, Xu Y, Ruggero D, 2021
The role of translation control in tumorigenesis and its therapeutic implications, Xu Y, Ruggero D, 2020
An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers, Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ, 2020
Translation control of the immune checkpoint in cancer and its therapeutic targeting, Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y, Stumpf CR, Ruggero D, 2019
Nuclear TARBP2 drives oncogenic dysregulation of RNA splicing and decay, Fish L, Navickas A, Culbertson B, Xu Y, Nguyen HCB, Zhang S, Hochman M, Okimoto R, Dill BD, Molina H, Najafabadi HS, Claudio Alarcón, Ruggero D, Goodarzi H, 2019
LMTK3 Represses Tumour Suppressor-Like Genes through Chromatin Remodeling in Breast Cancer, Xu Y, Zhang H, Nguyen V, Angelopoulos N, Nunes J, Reid A, Buluwela L, Magnani L, Stebbing J, Giamas G, 2015
The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin beta(1), Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, Lombardo Y, Frampton AE, Green AR, Ellis IO, Ali S, Lenz HJ, Thanou M, Stebbing J, Giamas G, 2014
Broader implications of SILAC-based proteomics for dissecting signaling dynamics in cancer, Zhang H, Xu Y, Papanastasopoulos P, Stebbing J, Giamas G, 2014
Targeting lemurs against cancer metastasis, Xu Y, Zhang H, Giamas G, 2014
Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics, Liu TY, Huang HH, Wheeler D, Xu Y, Wells JA, Song YS, Wiita AP, 2017
Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics, Stebbing J, Zhang H, Xu Y, Grothey A, Ajuh P, Angelopoulos N, Giamas G, 2015
KSR1 regulates BRCA1 degradation and inhibits breast cancer growth, Stebbing J, Zhang H, Xu Y, Lit LC, Green AR, Grothey A, Lombardo Y, Periyasamy M, Blighe K, Zhang W, Shaw JA, Ellis IO, Lenz HJ, Giamas G, 2015
Proteomic profile of KSR1-regulated signaling in response to genotoxic agents in breast cancer, Zhang H, Angelopoulos N, Xu Y, Grothey A, Nunes J, Stebbing J, Giamas G, 2015
LMTK3 is implicated in endocrine resistance via multiple signaling pathways, Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, Miki Y, Chow LW, Coombes RC, Sasano H, Shaw JA, Giamas G, 2013
SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1, Zhang H, Xu Y, Filipovic A, Lit LC, Koo CY, Stebbing J, Giamas G, 2013
Oestrogen attenuates tumour progression in hepatocellular carcinoma, Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J, Zhang W, Han X, Tan R, Shen P, 2012
Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs), Yang W, Lu Y, Xu Y, Xu L, Zheng W, Wu Y, Li L, Shen P, 2012
Proteomic profile of KSR1-regulated signaling in response to genotoxic agents in breast cancer, Angelopoulos N, Stebbing J, Xu Y, Giamas G, Zhang H, 2016

Tumor Pharmacology Mrna Translation Regulation Mechanism Drug Targeting Cancer Therapy

Hongrui Liu - Fudan University

Wenfu Tan - Fudan University

Zhiruo Zhou - Fudan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us